The pituitary adenylate cyclase activating peptide (PACAP) is a polypeptide with multiple biological activities, including PACAP-38 and PACA-27, which are composed of 38 and 27 amino acids, respectively. The amino acid sequence of the latter is the same as that of PACAP-38. The N-terminal 1-27 amino acid residues are exactly same. PACAP is widely distributed in animals, mainly in the nervous system and gastrointestinal tissues. PAC1R is its type 1 receptor (PAC1R), PAC1R is a G protein-coupled receptor (GPCR), and most of PAC1R and "seed" tau protein are located on the same side of the synapse.
The researchers used the pituitary adenylate cyclase activating peptide to stimulate its type 1 receptor (PAC1R). PAC1R is a G protein-coupled receptor (GPCR), and most of the PAC1R and the "seed" tau protein are located at the same synapse. side. The results show that after PACAP binds to PAC1R, 26S proteasome activity is enhanced, and the level of toxic tau protein is reduced. The cognitive ability of mice in the early stage of tau protein accumulation is also improved. Importantly, this peptide has a positive effect on the mutation. There is almost no effect on the other side of the touch. However, PACAP degrades rapidly in the body and is not an ideal treatment method. Therefore, it is necessary to develop effective PAC1R agonists.[1]
Our Services
- Provide PAC1R agonist design services, you can choose small molecule agonists or peptide agonists, we will provide corresponding solutions according to your needs.
- Provide molecular dynamics simulation, or coarse-grained dynamics simulation, to study the details of the interaction between small molecule agonists or peptide agonists and PACAP.
- Provide pharmacophore model construction service for feasibility assessment of new drug targets. By using the pharmacophore model, major adverse reactions can be predicted in the early stage of drug development, thereby reducing the possibility of drug development failure.
- Provide network analysis service to study the changes of the residue interaction network in the whole PACAP or near the binding site.
- Provide network analysis service to study the changes of the amino acid interaction network in the whole PACAP or near the binding site.
- Provide corresponding result analysis service.
Provided by Clients
Please inform us of the details about your PAC1R targeting research project after signing a non-disclosure agreement, which can be specific to the force field of molecular dynamics simulation, and the result analysis requirements.
Deliverables
- Small molecule agonist design results
- Peptide agonist design results
- Matching scoring results
- Raw data and result analysis of molecular dynamics simulation
- Analysis of pharmacophore results
- Analysis of residue interaction network results
- Other related data analysis
Our advantages
- The scientific research team of CD ComputaBio is composed of doctoral-level scientists and business managers with many years of work experience. They have professional technical level and can meet your various scientific research needs.
- CD ComputaBio cooperates with scientists from many pharmaceutical and biotechnology companies. We have a wealth of knowledge and experience to provide quality assurance services.
If you want to know more about PAC1R targeting services provided by CD ComputaBio, please contact us at any time.
Reference:
-
Ari W. Schaler et al. PAC1 receptor–mediated clearance of tau in postsynaptic compartments attenuates taupathology in mouse brain. Science Translational Medicine. 2021.
* For Research Use Only.
